Together, these advances underscore the TNFRSF1A/ITGB1/EGFR–CEBPD signaling axis and specific PTM processes—particularly S-nitrosylation—as promising, therapeutically actionable targets in MES2-like GBM. This evidence concerns the gene EGFR and glioblastoma.